Abstract
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have